tiprankstipranks
Trending News
More News >
Rhythm Biosciences Ltd. (AU:RHY)
ASX:RHY
Australian Market

Rhythm Biosciences Ltd. (RHY) AI Stock Analysis

Compare
5 Followers

Top Page

AU

Rhythm Biosciences Ltd.

(Sydney:RHY)

Rating:45Neutral
Price Target:
AU$0.00
▼( -100.00% Downside)
The overall stock score of 45 reflects significant financial performance challenges due to negative margins, declining revenues, and liquidity issues, which are the most impactful factors. The technical analysis suggests some short-term stability but overall bearish trends. Valuation metrics indicate ongoing losses and a lack of profitability, further reducing the stock's attractiveness.

Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)

Rhythm Biosciences Ltd. Business Overview & Revenue Model

Company DescriptionRhythm Biosciences Ltd. (RHY) is an Australian-based biotechnology company focused on the development and commercialization of medical diagnostics. The company's primary product, ColoSTAT, is a non-invasive, blood-based test designed for the early detection of colorectal cancer. Rhythm Biosciences aims to provide accurate, accessible, and affordable diagnostic solutions that enhance patient outcomes and support early disease intervention.
How the Company Makes MoneyRhythm Biosciences generates revenue through the commercialization and sales of its ColoSTAT diagnostic test. The company aims to sell its tests to healthcare providers, laboratories, and potentially directly to consumers, depending on regulatory approvals and market strategy. Key revenue streams include initial sales of the diagnostic tests, potential licensing agreements, and partnerships with healthcare institutions or pharmaceutical companies. The company's earnings are significantly influenced by its ability to successfully market ColoSTAT and secure regulatory approvals in various regions, which would expand its market reach and drive sales growth.

Rhythm Biosciences Ltd. Financial Statement Overview

Summary
Rhythm Biosciences Ltd. is experiencing significant financial challenges, with negative margins and declining revenues indicating operational difficulties. The balance sheet shows minimal leverage but decreasing equity, while cash flow metrics highlight liquidity issues and reliance on external financing. Improvement in revenue and cost efficiency is essential for stabilizing the financial position.
Income Statement
35
Negative
Rhythm Biosciences Ltd. has experienced a declining revenue trend, with revenue dropping significantly from 2023 to 2024. The company has negative gross and net profit margins, indicating continued operational losses. EBIT and EBITDA margins are also negative, reflecting ongoing challenges in achieving profitability. Despite past revenue growth, the current financial performance suggests significant room for improvement in income generation and cost management.
Balance Sheet
45
Neutral
The balance sheet reveals a small debt-to-equity ratio, which is a positive sign of minimal leverage. However, the return on equity is negative due to continued net losses, limiting shareholder returns. The equity ratio indicates modest equity financing, but declining asset and equity values year-over-year pose risks to financial stability.
Cash Flow
40
Negative
Free cash flow remains negative, though slightly improved from the previous year, indicating cash constraints. The operating cash flow to net income ratio is negative, which suggests cash outflows exceed earnings. Continued reliance on financing activities to cover operational shortfalls highlights liquidity challenges.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
5.59M1.69M3.10M2.43M1.11M100.00K
Gross Profit
4.02M-1.36M2.91M2.33M961.86K-41.29K
EBIT
-3.50M-6.71M-11.54M-11.25M-6.61M-4.02M
EBITDA
-2.02M-6.80M-11.11M-11.10M-6.47M-3.87M
Net Income Common Stockholders
-2.18M-6.86M-8.22M-6.32M-7.72M-4.13M
Balance SheetCash, Cash Equivalents and Short-Term Investments
4.45M754.50K4.17M7.60M2.27M1.84M
Total Assets
5.93M1.52M7.70M8.44M3.07M2.65M
Total Debt
158.66K163.82K84.61K170.14K0.0042.44K
Net Debt
-4.21M-545.67K-4.04M-7.38M-2.23M-1.76M
Total Liabilities
1.05M651.54K1.82M1.07M1.36M802.85K
Stockholders Equity
4.88M867.17K5.87M7.37M1.71M1.84M
Cash FlowFree Cash Flow
-2.12M-6.22M-7.06M-6.24M-5.47M-2.79M
Operating Cash Flow
-2.12M-6.14M-6.96M-6.21M-5.40M-2.74M
Investing Cash Flow
-561.35K-82.28K-99.12K-27.01K-68.27K-45.53K
Financing Cash Flow
5.83M2.80M3.63M11.85M5.90M-142.22K

Rhythm Biosciences Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.06
Price Trends
50DMA
0.07
Negative
100DMA
0.08
Negative
200DMA
0.08
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
62.55
Neutral
STOCH
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHY, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 62.55 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RHY.

Rhythm Biosciences Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURMD
79
Outperform
AU$54.52B27.9825.23%0.82%10.54%38.69%
AUNAN
76
Outperform
$1.38B83.159.23%10.79%5.20%
AUCOH
72
Outperform
$17.55B47.4320.61%1.68%6.35%5.97%
AUCSL
64
Neutral
$119.30B28.6315.38%1.70%8.00%9.09%
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
AURHY
45
Neutral
AU$17.68M-71.10%76.17%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:RHY
Rhythm Biosciences Ltd.
0.07
0.00
0.00%
AU:CSL
CSL
247.05
-30.67
-11.04%
AU:NAN
Nanosonics Limited
4.44
1.55
53.63%
AU:COH
Cochlear
269.75
-45.40
-14.41%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
37.39
6.06
19.34%

Rhythm Biosciences Ltd. Corporate Events

Rhythm Biosciences Advances ColoSTAT® Kit Towards Commercialization
May 25, 2025

Rhythm Biosciences Ltd has successfully completed the verification and validation of its second-generation ColoSTAT® assay Beta kits, marking a significant step towards commercialization. The optimized kits, designed for routine lab use, have demonstrated improved performance, reduced turnaround times, and cost efficiency. The company is now transitioning to the final manufacturing stage with its partner Quansys, aiming for commercial availability following further testing and accreditation. This advancement strengthens Rhythm’s position in the cancer diagnostics industry and promises to enhance colorectal cancer detection, potentially reducing mortality and healthcare costs.

Rhythm Biosciences Secures Contract for Breast Cancer Risk Study with University of Melbourne
May 15, 2025

Rhythm Biosciences Ltd has announced a 12-month contract through its subsidiary Genetype with the University of Melbourne to provide geneType™ Breast Cancer Risk assessment. This partnership aims to enhance breast cancer screening for Australian women aged 40-59 by integrating personalized risk assessment approaches, which align with national guidelines. The study will incorporate factors like family history, mammographic breast density, and polygenic risk scores, potentially setting a new standard for risk-stratified screening. This collaboration not only accelerates Genetype’s commercial growth but also strengthens its market position in predictive cancer diagnostics, offering significant implications for stakeholders by potentially improving the effectiveness of breast cancer screening and expanding the use of personalized risk models.

Rhythm Biosciences Issues New Unquoted Securities
May 2, 2025

Rhythm Biosciences Ltd. announced the issuance of 401,716 unquoted securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move reflects the company’s ongoing strategic financial maneuvers to support its operations and growth within the biotechnology sector, potentially impacting its market positioning and stakeholder interests.

Rhythm Biosciences Announces Proposed Securities Issue
May 1, 2025

Rhythm Biosciences Ltd. announced a proposed issue of securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance, involving a total of 401,716 securities, is aimed at raising capital to support the company’s operational and strategic initiatives. The announcement reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence in the biotechnology sector.

Rhythm Biosciences Advances ColoSTAT® and Expands Product Portfolio
Apr 24, 2025

Rhythm Biosciences Ltd has announced significant progress in its ColoSTAT® Beta kits, which are in the final verification phase and preparing for clinical validation. The company has also successfully integrated the Genetype business and relaunched the geneType™ product portfolio, achieving its first commercial sales. These developments, alongside strategic management enhancements, position Rhythm Biosciences to strengthen its operations and market presence, with expectations for further milestones in the upcoming quarters.

Rhythm Biosciences Secures Extended ISO Certification, Bolstering Market Strategy
Apr 14, 2025

Rhythm Biosciences Ltd has successfully maintained its ISO 13485:2016 certification for the seventh consecutive year, with an extended scope that now includes hardware development as part of its ColoSTAT® system. This certification supports the company’s market entry strategy by enhancing regulatory approvals and market confidence, reinforcing its operational credibility, and validating its robust quality systems. The certification is crucial for the international launch of ColoSTAT® and the company’s ability to supply high-quality raw materials for in-house IVD applications.

Rhythm Biosciences Announces Quotation of New Securities
Apr 11, 2025

Rhythm Biosciences Ltd. has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). The company is set to quote 33,333,331 options expiring on March 31, 2026, as part of previously announced transactions. This move could potentially enhance the company’s financial flexibility and support its ongoing projects in the biotechnology sector.

FIL Limited Increases Stake in Rhythm Biosciences
Apr 8, 2025

Rhythm Biosciences Ltd. has seen a change in its substantial holdings, with FIL Limited increasing its voting power from 5.04% to 6.04% as of April 4, 2025. This increase in shares reflects a strategic move by FIL Limited, potentially signaling confidence in Rhythm Biosciences’ market position and future prospects, which could have implications for stakeholders and the company’s operations.

Rhythm Biosciences Secures Shareholder Support at EGM
Mar 31, 2025

Rhythm Biosciences Ltd announced that all resolutions at their Extraordinary General Meeting were successfully passed. This outcome reflects strong shareholder support and is expected to positively impact the company’s strategic initiatives and market positioning, particularly in the field of cancer diagnostics.

Rhythm Biosciences Unveils Investor Presentation on Cancer Diagnostic Innovations
Mar 30, 2025

Rhythm Biosciences Ltd. has released an investor presentation highlighting its ongoing efforts in the biotechnology sector, particularly in cancer diagnostics. The presentation serves as a general information guide and includes forward-looking statements subject to change, emphasizing the company’s commitment to advancing its research and development initiatives. Stakeholders are advised to consider the inherent uncertainties and risks associated with the company’s projections.

Rhythm Biosciences Reports First Commercial Sales of geneType™ Products
Mar 18, 2025

Rhythm Biosciences Ltd has announced the first commercial sales of its geneType™ products following the acquisition of Genetype in December 2024. The company anticipates significant sales growth driven by enterprise market focus, geographic expansion, and support from key opinion leaders. The geneType™ platform offers comprehensive risk assessments for various diseases, positioning Rhythm well in the preventative healthcare market. The company also plans to expand revenues with ColoSTAT® sales in the next financial year, further strengthening its market position.

Rhythm Biosciences Issues Unquoted Securities to Employees
Mar 18, 2025

Rhythm Biosciences Ltd. announced the issuance of 750,000 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational efficiency and stakeholder engagement by aligning employee interests with company performance.

Rhythm Biosciences Appoints New CFO Amid Global Growth Plans
Mar 17, 2025

Rhythm Biosciences Ltd has announced the appointment of Todd Perkinson as the new Chief Financial Officer. Perkinson brings extensive experience in financial management and business transformation, having successfully led major mergers, acquisitions, and business turnarounds in previous roles. His appointment comes as Rhythm prepares for significant global growth, indicating a strategic move to enhance its financial leadership and operational efficiency. This development is expected to strengthen Rhythm’s industry positioning and support its mission to expand its innovative cancer diagnostics solutions globally.

Rhythm Biosciences Announces Cessation of Employee Securities
Mar 17, 2025

Rhythm Biosciences Ltd. announced the cessation of 1,000,000 ordinary fully paid employee securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for employee incentives and stakeholder confidence.

Rhythm Biosciences Issues Investor Presentation with Cautionary Notes
Mar 5, 2025

Rhythm Biosciences Limited has released an investor presentation, emphasizing that the information provided is for general purposes and not intended as investment advice. The presentation includes forward-looking statements subject to risks and uncertainties, and the company disclaims any liability for the accuracy or completeness of the information, which may change based on further research.

Rhythm Biosciences Announces 2025 Extraordinary General Meeting
Feb 27, 2025

Rhythm Biosciences Limited has announced an Extraordinary General Meeting to be held on March 31, 2025, at the Offices of K&L Gates in Melbourne, Victoria. This hybrid meeting will allow shareholders to participate both in person and online. The meeting is crucial as it affects shareholder voting rights, and the company encourages shareholders to vote either in person or by proxy to ensure their voices are heard.

Rhythm Biosciences Hosts Investor Webinar on Strategic Developments
Feb 27, 2025

Rhythm Biosciences Ltd announced an investor webinar to discuss their half-year report, progress on the ColoSTAT® test for colorectal cancer detection, and the integration of Genetype assets. The ColoSTAT® test, a simple blood-based test, aims to provide an alternative for those unable or unwilling to participate in current screening programs, potentially reducing mortality rates and healthcare costs. The acquisition of Genetype enhances Rhythm’s capabilities in genetic risk assessment, positioning the company to meet growing demand in preventative healthcare and precision medicine markets.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.